Meet the scientists in BioLaminas booth at ISSCR 2017

MEET THE SCIENTISTS
IN BIOLAMINA'S BOOTH

Friday 16 June at 6:00PM-8:00PM
In BioLamina's Booth: #300


Biolamina will be hosting an informal networking event in our booth where you will have the opportunity to meet Drs. Roger Barker, Fredrik Lanner and Anna Falk. They will give a brief presentation of their latest research and you will have the opportunity to mingle with them, discuss your science and ask technical questions. Click HERE to download the poster.
No pre-registration needed!


More information about the speakers:

Fredrik Lanner
Assistant Professor at Karolinska Institutet and Karolinska University Hospital, Sweden

Anna Falk
Assistant Professor and Director of the iPS Core Facility at Karolinska Institutet, Sweden

Roger Barker
Professor at Cambridge University, UK and Visiting Professor at Lund University, Sweden

Malin Parmar
Professor at Lund University, Sweden

Innovation Showcase

Thursday, June 15 at 11:30 AM - 12:30 PM
Location: Level 3, Ballroom East


CORNING INC. - ADVANCES IN PATIENT DERIVED DISEASE MODELLING: FROM STANDARDIZED REPROGRAMMING OF IPS CELLS TO GENERATION OF HUMAN KIDNEY ORGANOIDS

Anna Falk                                                                                        
Associate Professor, Karolinska Institute, Sweden                              

Benjamin Freedmam
University of Washington, United States
 
Keith Olsen
Corning Life Sciences, United States
 
Paula Flaherty
Corning Life Sciences, United States

 

 

 

 

 

  Tissue Specific Laminins Generate Clinically Compliant hPSC Cultures for Clinical Trials

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  Clinically Compliant Human PSC Culture Conditions Support Efficient Clonal Survival and Rapid Scale-Up on laminin-521 

Our Posters

BioLamina's posters at ISSCR 2017 Annual Meeting
Boston June 14 - 17


Abstract ID: T-2066
Presented on Thursday, June 15, 2017 at 7:00PM-8:00PM

Tissue Specific Laminins Generate Clinically Compliant hPSC Cultures for Clinical Trials 

Louise Hagbard, Zhijie Xiao, Therese Kallur, Jesper Ericsson and Yi Sun, BioLamina AB, Sundbyberg, Sweden


The lack of defined, xeno-free, robust methods for efficient expansion and specialization of human pluripotent stem cells (hPSC) towards different cell types has hindered both the advancement of basic research and the translation into clinical settings.

The expression and composition of the basement membrane proteins are essential for embryonic morphogenesis and adult tissue functions. Laminins influence adhesion, differentiation, migration, phenotypic stability, anoikis resistance and functionality of all cells associated to it. Laminins are the only basement membrane proteins that are tissue specific and with the use of the specific combination of xeno-free and defined human recombinant laminins, the natural environment for each specific cell type can be created, generating high quality cell with homogenous phenotypes.

Laminin-521 (LN-521) is a protein naturally expressed by human PSCs and is a critical factor of the pluripotent stem cell niche. Human PSCs on LN-521 expand twice as fast compared to other matrices and can be cultured as single cells without the addition of ROCK inhibitor. PSCs on Ln-521 grow as a homogenous monolayer without any abnormal genetic aberrations and with maintained expression of pluripotency markers.

 By using different laminins, differentiation of LN-521 cultured hPSCs can be made robust, reliable and with increased efficiency, for example:

  • dopaminergic progenitors cultured on laminin-111 (LN-111), result in an increased yield of >40 times compared to standard EB-based protocols. The GMP-compatible LN-111 based protocol gives a very homogenous population of cells predicted to have a good graft outcome. Due to the high yield, the cost of reagent per transplant is low.
  • hESC-derived RPE cells cultured on LN-521 exhibit native characteristics including morphology, pigmentation, marker expression, polarization and phagocytic activity. Transplanted cells exhibit long-term integration and photoreceptor rescue capacity.
  • hESC cultured on LN521 and LN111 exhibit efficient hepatocyte specification, maturation, function and stabilization of phenotype. The cells are highly organized and exhibit a significant increase in P450 metabolic enzyme functions. 
  • LN-521 dramatically improves muscle cell proliferation and differentiation performance with more consistent and reliable differentiation over long-term culture.


Laminin coating substrates, compatible with GMP requirements, are currently being developed which allow the transition of these pre-clinical research protocols into clinical settings.

 

Abstract ID: F-2023
Presented on Friday, June 16, 2017 at 6:00PM-7:00PM

Clinically Compliant Human PSC Culture Conditions Support Efficient Clonal Survival and Rapid Scale-Up 

Therese Kallur, Louise Hagbard, Jesper Ericsson, Zhijie Xiao and Yi Sun, BioLamina AB, Sundbyberg, Sweden


The lack of defined, xeno-free, easy and robust methods for efficient expansion of human pluripotent stem cells (PSCs) has hindered both the advancement of basic research and human cell therapy, much due to high experimental variation and poor quality cells with phenotypic and genetic changes.

Laminin-521 (LN-521) is a protein naturally expressed by human PSCs and is a critical factor of the pluripotent stem cell niche. Laminins influence adhesion, differentiation, migration, phenotypic stability, anoikis resistance and functionality of all cells associated to it.  

LN-521 is a human and recombinant protein and can easily be used as a cell culture substrate. Human PSCs grow as a homogenous monolayer on LN-521, without any abnormal genetic aberrations and with maintained expression of pluripotency markers. Human PSCs on LN-521 expand twice as fast compared to other matrices and can be split 1:20 or up to 1:30 as single cells without the addition of ROCK inhibitor. Furthermore, LN-521 can be used as microcarrier coating for generating clinically relevant quantities of human PSCs thus offering a scalable and GMP-compatible bioprocessing platform.

Moreover, true clonal culture, important for cell fate tracking, gene function analyses and editing, is possible by using LN-521. Human embryonic stem cell (hESC) lines can even be derived from a single blastomere under chemically defined and xeno-free condition on LN-521, thereby circumventing the ethical issues associated with hESCs.

The simplicity and reliability of the culture procedure, the rapid cell amplification and the genetic stability of the cells make LN-521 a suitable as reagent in clinical trials for human PSC-based therapy.

In conclusion, we show that LN-521 is an optimal matrix for human PSC culture due to its biological relevance that allows derivation, clonal cultivation, stable long-term pluripotent cell growth and scalability. The robust method allows minimum culture maintenance and standardized protocols, which can easily be adapted to automation platforms, making LN-521 a suitable reagent choice for human cell therapy trials.